Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 15/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neurokinin B SCHEMBL29440672 | 1.00 | GRPR (0.59) | GRPR | |
| SCHEMBL30350156 | 0.94 | TACR3 (0.57) | GRPR | |
| SCHEMBL29406603 | 0.90 | CTSB (0.54) | — | |
| Neurokinin A SCHEMBL29374005 | 0.88 | PTH1R (0.62) | — | |
| Neurokinin A SCHEMBL29374084 | 0.88 | PTH1R (0.62) | — | |
| Neurokinin B SCHEMBL29372314 | 0.88 | GRPR (0.53) | GRPR | |
| SCHEMBL29569383 | 0.87 | OPRM1 (0.57) | GRPR | |
| SCHEMBL29678561 | 0.86 | CCKAR (0.51) | — | |
| SCHEMBL29678344 | 0.84 | NPY4R (0.56) | — | |
| SCHEMBL14364816 | 0.84 | GRPR (0.58) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260034249-A1 | COMPOSITIONS AND METHODS FOR MODIFYING FERTILITY | THE BROAD INSTITUTE, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3966224-B1 | METHODS FOR THE FRACTIONATION OF PROTEINS | UNIV SYDNEY (AU) | 2026-01-28 | — | — | EP | disclosed |
| US-12516083-B2 | Nucleophilic catalysts for oxime linkage | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-06 | — | — | US | disclosed |
| EP-4410288-B1 | TREATING TOURETTE SYNDROME | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250127771-A1 | METHODS OF DIAGNOSING AND TREATING TOURETTE SYNDROME | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250129423-A1 | ASSOCIATION OF RARE RECURRENT GENETIC VARIATIONS TO ATTENTION-DEFICIT, HYPERACTIVITY DISORDER (ADHD) AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF THE SAME | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250120962-A1 | NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATORS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND 22Q SYNDROME | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-04-17 | — | — | US | disclosed |
| CN-119698466-A | Compositions and methods for NK cell differentiation | 优莫佳生物制药股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119677772-A | Engineered stem cells and uses thereof | 优莫佳生物制药股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20220204553-A1 | METHODS FOR THE FRACTIONATION OF PROTEINS | THE UNIVERSITY OF SYDNEY (AU) | 2022-06-30 | — | — | US | disclosed |
| EP-4019049-A1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | Takeda Pharmaceutical Company Limited (JP) | 2022-06-29 | — | — | EP | disclosed |
| US-20220117953-A1 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220117954-A1 | METHODS OF DIAGNOSING AND TREATING ANXIETY DISORDER | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2022-04-21 | — | — | US | disclosed |
| US-11298347-B2 | Methods of diagnosing and treating Tourette syndrome | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3977996-A1 | METHODS OF DIAGNOSING AND TREATING TOURETTE SYNDROME | The Children's Hospital Of Philadelphia (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-2849795-B1 | METHODS FOR PREPARING THERAPEUTIC PROTEIN-POLYMER CONJUGATES | TAKEDA PHARMACEUTICALS CO (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3964213-A1 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | The Children's Hospital Of Philadelphia (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022038131-A1 | METHOD FOR THE PREDICTION OF PROGRESSION OR PROGNOSIS OF THE RESPONSE OF A SUBJECT SUFFERING FROM ACUTE ORGAN DAMAGE | Plus Vitech, S.L. (ES) | 2022-02-24 | — | — | WO | disclosed |
| EP-3347013-B1 | NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATOR FOR TREATMENT OF ATTENTION DEFICIT DISORDER | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298347-B2 | Methods of diagnosing and treating Tourette syndrome | GRM2, GRM4, GRM1 | GRPR 2620/4885 |
| US-20250127771-A1 | METHODS OF DIAGNOSING AND TREATING TOURETTE SYNDROME | GRM2, GRM4, GRM1 | GRPR 2620/4885 |
| US-20250120962-A1 | NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATORS FOR TREATMENT OF ATTENTION DEFICIT DISORDER AND 22Q SYNDROME | GRM2, GRM6, GRM4 | GRPR 1444/4885 |
| US-20260034249-A1 | COMPOSITIONS AND METHODS FOR MODIFYING FERTILITY | PGRMC2, TAGLN2, PGRMC1 | GRPR 4722/4885 |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | GRM8, GRM4, GRIA4 | GRPR 3100/4885 |
| US-20220117953-A1 | METHODS OF DIAGNOSING AND TREATING CONDUCT DISORDER | GRM4, GRM6, GRM2 | GRPR 2017/4885 |
| US-20220117954-A1 | METHODS OF DIAGNOSING AND TREATING ANXIETY DISORDER | GRM4, GRM2, GRM6 | GRPR 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.